We are live on ! Find out more
ADAP

Adaptimmune Therapeutics

Delisted

ADAP was delisted on the 27th of October, 2025.

79 hedge funds and large institutions have $397M invested in Adaptimmune Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,555% more call options, than puts

Call options by funds: $2.25M | Put options by funds: $136K

10% more capital inflows, than outflows

Capital inflows: $74.7M | Capital outflows: $67.8M

2.22% more ownership

Funds ownership: 41.95% → 44.17% (+2.2%)

8% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 24

15% less funds holding

Funds holding: 93 → 79 (-14)

50% less funds holding in top 10

Funds holding in top 10: 6 → 3 (-3)

58% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 26

Holders
79
Holders Change
-14
Holders Change %
-15.05%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
11
Increased
26
Reduced
24
Closed
26
Calls
$2.25​M
Puts
$136​K
Net Calls
+$2.12​M
Net Calls Change
-⁠$5.62​M

ADAP Hedge Fund Activity: Q4 2018 in Review

79 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2018, worth a combined $397M — down 55% from $888M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ADAP and 11 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 26 added.

The largest buyer was Matrix Capital Management Company, adding an estimated $50.1M. The largest seller was Frontier Capital Management, exiting entirely with an estimated $9.47M sold.

  • 79 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2018, down from 93 in Q3 2018.
  • Funds reported $397M of Adaptimmune Therapeutics stock for Q4 2018, down 55% quarter-over-quarter.
  • 11 funds opened new Adaptimmune Therapeutics positions in Q4 2018 and 26 closed out, a net change of -15 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2018 was Matrix Capital Management Company, an estimated $50.1M added.
  • The largest Adaptimmune Therapeutics seller in Q4 2018 was Frontier Capital Management, an estimated $9.47M sold.

Based on aggregated 13F filings for Q4 2018.